Liberal blood transfusion strategy does not improve outcomes in acute MI patients with anemia: MINT study
A strategy of administering a transfusion only when the hemoglobin level falls below 7 or 8 g/dL has been widely adopted. But can a liberal transfusion strategy (hemoglobin threshold, <10 g/dL) among patients with an acute myocardial infarction and anemia improve outcomes in these patients remains debatable. A recent study published in this regard in NEJM and simultaneously presented at AHA 2023 meet has compared the restrictive strategy with more liberal one and found that the latter fails to significantly reduce the risk of recurrent myocardial infarction or death at 30 days.
From a mechanistic perspective, blood transfusion may decrease ischemic injury by improving oxygen delivery to myocardial tissues and reduce the risk of reinfarction or death. Alternatively, administering more blood could result in more frequent heart failure from fluid overload, infection from immunosuppression, thrombosis from higher viscosity, and inflammation.
The primary objective of the MINT trial was to determine whether the risk of death or myocardial infarction through 30 days differed between a restrictive transfusion strategy (hemoglobin threshold, 7 to 8 g/dL) and a liberal transfusion strategy (hemoglobin threshold, <10 g/dL) among patients with an acute myocardial infarction and anemia.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.